Molecular alterations in malignant disease result in the expression or upregulations of
various targets that can be used for imaging and treatment with radiopharmaceuticals. This …

Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have
been used for more than 20 y. An important improvement in recent years was the …

Purpose Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy
(RLT) with limited side effects. Our aim was to perform image-based absorbed dose …

In recent years, several radioligands targeting prostate-specific membrane antigen (PSMA)
have been clinically introduced as a new class of theranostic radiopharmaceuticals for the …

Purpose Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed
injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses …

Molecular targeted therapy plays an increasingly important role in the treatment of metastatic
pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain …

Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …

Purpose The β¯-emitting terbium-161 also emits conversion and Auger electrons, which are
believed to be effective in killing single cancer cells. Terbium-161 was applied with …

MATERIALS AND METHODS Systematic Review To inform the development of these
guidelines, a systematic review of evidence was performed. We followed the Preferred …

Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …